Get the Stockscreener App
111.62
1.05%
-1.18
After Hours:
110.09
-1.53
-1.37%
Corcept Therapeutics Inc stock is traded at $111.62, with a volume of 601.52K.
It is down -1.05% in the last 24 hours and up +1.66% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$112.80
Open:
$110.59
24h Volume:
601.52K
Relative Volume:
0.55
Market Cap:
$12.07B
Revenue:
$769.10M
Net Income/Loss:
$46.67M
P/E Ratio:
318.91
EPS:
0.35
Net Cash Flow:
$119.79M
1W Performance:
-1.98%
1M Performance:
+1.66%
6M Performance:
+212.75%
1Y Performance:
+60.91%
1-Day Range:
$109.26
$112.13
1-Week Range:
$108.72
$115.85
52-Week Range:
$28.66
$126.38
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
111.62 | 13.09B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-26 | Upgrade | UBS | Neutral → Buy |
| Mar-26-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Therapeutics stock hits all-time high at 122.5 USD By Investing.com - Investing.com Canada
Corcept Therapeutics(CORT.US) Director Sells US$12.25 Million in Common Stock - Moomoo
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT) - Yahoo Finance
Zacks Research Has Bullish Forecast for CORT Q3 Earnings - MarketBeat
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164 - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Stock - MarketBeat
Corcept (NASDAQ: CORT) exec sells 10,000 shares at $116 - Stock Titan
Corcept (NASDAQ: CORT) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Corcept (NASDAQ: CORT) director plans open-market sale of 103,606 shares - Stock Titan
Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating - marketscreener.com
Truist assumes Corcept Therapeutics stock with buy rating on Cushing’s opportunity - Investing.com Nigeria
CORCEPT THERAPEUTICS INC SEC Filing (Aug 17, 2026) - Stock Titan
CORT Looks 65.7% Overvalued on GF Value™ - GuruFocus
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026 (XLV:NYSEARCA) - Seeking Alpha
23,257 Shares in Corcept Therapeutics Incorporated $CORT Purchased by GSA Capital Partners LLP - MarketBeat
Corcept therapeutics chief development officer sells $1.8m in stock - Investing.com
Corcept therapeutics chief development officer sells $1.8m in stock By Investing.com - Investing.com Canada
Corcept Therapeutics (CORT) CBO reports 17,530-share stock gifts and trust holdings - Stock Titan
Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics - Stock Titan
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Sean Maduck Sells 1,031 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock - MarketBeat
William Guyer Sells 16,300 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock - MarketBeat
Corcept chief development officer sells $418,561 of stock By Investing.com - Investing.com Nigeria
Corcept chief development officer sells $418,561 of stock - Investing.com
Sei Investments Co. Sells 62,377 Shares of Corcept Therapeutics Incorporated $CORT - marketbeat.com
Amundi Acquires New Shares in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline (PR Newswire) - Aktiellt
California State Teachers Retirement System Boosts Stake in Corcept Therapeutics Incorporated $CORT - marketbeat.com
12,478 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Evanson Financial LLC - MarketBeat
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance UK
Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales - Yahoo Finance
Corcept CDO William Guyer sells $418,561 in common stock By Investing.com - Investing.com South Africa
Corcept CDO William Guyer sells $418,561 in common stock - Investing.com
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 3,700 Shares - MarketBeat
Janus Henderson Group PLC Acquires 10,817 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Insider Sells 20,305 Shares of Stock - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 1,540 Shares of Stock - MarketBeat
Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation - Yahoo Finance
Corcept Therapeutics' (NASDAQ:CORT) Anemic Earnings Might Be Worse Than You Think - Moomoo
Parallel Advisors LLC Buys 96,763 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT (NASDAQ: CORT) insider schedules 20,000-share option-related sale - Stock Titan
John Hussman's Top Q2 2026 Move: Exiting Corcept Therapeutics In - GuruFocus
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) CFO Sells $9,176,800.00 in Stock - MarketBeat
Corcept Therapeutics (CORT) CFO exercises options and sells 80,000 shares - Stock Titan
CORCEPT THERAPEUTICS INC SEC Filing (Aug 3, 2026) - Stock Titan
FAS Wealth Partners Inc. Grows Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Perceptive Advisors LLC Takes Position in Corcept Therapeutics Incorporated $CORT - marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Upgraded at Wall Street Zen - MarketBeat
Corcept: Commercial Evidence™ with Agentic Call Report - Veeva
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know - webull.com
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Park Kimberly | Director |
Aug 26 '26 |
Sale |
122.55 |
26,685 |
3,270,169 |
0 |
| Maduck Sean | See Remarks |
Aug 25 '26 |
Option Exercise |
11.35 |
30,955 |
351,339 |
40,710 |
| Maduck Sean | See Remarks |
Aug 25 '26 |
Sale |
125.58 |
30,955 |
3,887,320 |
9,755 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):